Literature DB >> 6489

Characterization of the protease activity in the chemotactic factor inactivator.

P A Ward, J Ozols.   

Abstract

The chemotactic factor inactivator (CFI) isolated from human serum contains a kininase activity that causes extensive hydrolysis of bradykinin. The highly chemotactic synthetic peptide Met-Leu-Phe was completely hydrolyzed by CFI preparations. The release of the constituent amino acids from this peptide coincided with a loss of its chemotactic activity. The N-formyl, but not the amide derivative, of the leukotactic peptide Met-Leu-Phe was resistant to the action of CFI, as evidenced by chemotactic and biochemical assays. Examination of the specificity of CFI proteolysis revealed that short polypeptide substrates are degraded sequentially from the amino terminus. Larger peptides are less extensively hydrolyzed, and the patterns of hydrolysis are more complex. Inactivation of the bacterial chemotactic factors by CFI was overcome by the addition of high concentrations of peptides which were substrated for CFI. CFI preparations readily hydrolyzed the peptide Arg-Phe-Ala. The constituent amino acids were conveniently identified by thin-layer chromatography method. This procedure afforded a rapid assay for measuring CFI activity in the whole human serum as well as in fractions throughout the purification steps. Moreover, CFI also hydrolyzed L-leucyl-beta-napthylamide at rates comparable to peptides. Thus, L-leucyl-beta-napthylamide served as a useful substrate for estimating CFI activity in preparations at various stages of purification. This substrate was also useful in kinetic studies. The results from these studies indicate an aminopeptidase activity is the mechanism whereby CFI inhibits the activity of chemotactic substrates.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6489      PMCID: PMC333162          DOI: 10.1172/JCI108440

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  The colorimetric determination of leucine aminopeptidase in urine and serum of normal subjects and patients with cancer and other diseases.

Authors:  J A GOLDBARG; A M RUTENBURG
Journal:  Cancer       Date:  1958 Mar-Apr       Impact factor: 6.860

2.  The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli.

Authors:  E Schiffmann; H V Showell; B A Corcoran; P A Ward; E Smith; E L Becker
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Cytochrome b5 from microsomal membranes of equine, bovine, and porcine livers. Isolation and properties of preparations containing the membranous segment.

Authors:  J Ozols
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

5.  N-formylmethionyl peptides as chemoattractants for leucocytes.

Authors:  E Schiffmann; B A Corcoran; S M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

6.  Two distinct chemotactic factor inactivators in human serum.

Authors:  G Till; P A Ward
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

7.  Antileukotactic properties of tumor cells.

Authors:  J P Brozna; P A Ward
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

9.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  8 in total

1.  The regulation of tissue eosinophil chemotactic factor and inhibitor in allergic skin lesions of Freund's complete adjuvant-treated guinea-pigs.

Authors:  M Hirashima; K Tashiro; H Hayashi
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

2.  A chemotactic inhibitor in synovial fluid.

Authors:  Y Matzner; R E Partridge; B M Babior
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

3.  Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system.

Authors:  R A Clark; S J Klebanoff
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

4.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

5.  Neutrophil function in infection-prone children.

Authors:  L Håkansson; T Foucard; R Hällgren; P Venge
Journal:  Arch Dis Child       Date:  1980-10       Impact factor: 3.791

6.  Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

Authors:  K J Johnson; T P Anderson; P A Ward
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

7.  Regulatory dysfunction in leukotaxis.

Authors:  P A Ward; K J Johnson; D L Kreutzer
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

8.  Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.

Authors:  S M Hanlon; G S Panayi; R Laurent
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.